

## Use of a BMI-independent biomarker-based prostate cancer risk score to identify and triage individuals at risk of prostate disease

Joanne Watt<sup>1</sup>, Allister Irvine<sup>1</sup>, Mary Jo Kurth<sup>1</sup>, Laura Mooney<sup>1</sup>, Gary Smyth<sup>2</sup>, Hardev Pandha<sup>3</sup>, John Lamont<sup>1</sup>, Peter Fitzgerald<sup>1</sup>, Le Roy Dowey<sup>#4</sup>, Mark W Ruddock<sup>#5 6</sup>

<sup>1</sup>Randox Laboratories Ltd., 55 Diamond Road, Crumlin, Antrim, BT29 4QY, UK. <sup>2</sup>Randox Health GB, 143-149 Great Portland Street, Marylebone, London, W1W 6QN, UK. <sup>3</sup>Research Development and Innovations Department, Royal Surrey County Hospital NHS Foundation Trust, The Royal Surrey County Hospital, Guildford, GU2 7XX, UK. <sup>4</sup>School of Biomedical Sciences, Ulster University, Coleraine, Londonderry, BT52 1SA, UK. <sup>5</sup>Randox Laboratories Ltd., 55 Diamond Road, Crumlin, Antrim, BT29 4QY, UK. <sup>6</sup>Randox Health GB, 143-149 Great Portland Street, Marylebone, London, W1W 6QN, UK.

Prostate cancer (PCa) is the second most common cause of cancer related deaths in men in the UK. A national screening programme for PCa does not exist due to the unsuitability of the total prostate specific antigen (tPSA) test which is not specific for PCa and has a high false positive rate. Serum tPSA was measured in n = 25,356 male Randox Health clients. A biomarker-based (tPSA, EGF, MCP-1, IL-8) prostate cancer risk score (PCRS) was then applied to a retrospective cohort (n = 1,142/25,356) of individuals to assess PCa risk. A comparative analysis between tPSA and PCRS indicated that 90.5% of the cohort were assigned low risk of PCa. Of those with an elevated PCRS, 67.8% (78/115) had a normal tPSA value based on tPSA age-adjusted cut-offs. In addition, we observed a significant negative correlation between increasing body mass index (BMI) in men with high BMI ( $\geq 30$ ) and tPSA levels. No correlation was observed between BMI and PCRS. The tPSA test is potentially unsuitable for use in males with BMI  $\geq 30$ . Use of PCRS could provide more accurate PCa risk stratification for males with BMI  $\geq 30$ . Future assessment of the clinical utility of PCRS is warranted.